Pressmeddelanden från Herantis Pharma

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Herantis Pharma

Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases 05 mar 13:00

Herantis Pharma

Herantis Pharma releases 2H and FY 2025 report today 19 feb 16:35

Herantis Pharma

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096 07 jan 19:01

Herantis Pharma

Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease 26 nov 2025 13:00

Herantis Pharma

Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096 07 okt 2025 19:24

Herantis Pharma

Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease 21 aug 2025 07:19

Herantis Pharma

Herantis Pharma releases 1H 2025 report today 14 aug 2025 15:02

Herantis Pharma

Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease 13 maj 2025 08:05

Herantis Pharma

First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease 04 nov 2024 11:00

Herantis Pharma

Herantis Pharma presenterar på BioStock Life Science Summit 20 november 04 nov 2024 11:00

Herantis Pharma

Herantis Pharma will present at the BioStock Life Science Summit, November 20 06 mar 2024 07:00

Herantis Pharma

Herantis julkaisee vuoden 2023 toisen vuosipuoliskon katsauksen ja vuoden 2023 tilinpäätöksen 04 mar 2024 08:30

Herantis Pharma

Herantis Pharma: HER-096 edistää solustressistä kärsivien hermosolujen toiminnallista palautumista ja uusiutumista – kaksi posteriesitystä AD/PD 2024 -konferenssissa 19 feb 2024 09:00

Herantis Pharma

Kutsu Herantis Pharman webinaariin: Yhtiön puolivuosikatsaus ja vuoden 2023 tilinpäätös 6.3.2024 12 feb 2024 08:00

Herantis Pharma

Herantis Pharma osallistuu 19th Annual Biomarkers Congress- ja Biotechgate Digital Partnering -tapahtumiin 26 jan 2024 11:50

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle 15 jan 2024 11:30

Herantis Pharma

Osakkeenomistajien nimitystoimikunnan ehdotukset Herantis Pharma Oyj:n varsinaiselle yhtiökokoukselle 2024 18 dec 2023 12:05

Herantis Pharma

Herantis Pharma osallistuu vuosittaiseen J. P. Morgan Healthcare -viikon tapahtumiin San Franciscossa 13 dec 2023 16:10

Herantis Pharma

Herantis Pharma’s financial calendar and annual general meeting for 2024 13 dec 2023 16:05

Herantis Pharma

Herantis Pharma Oyj: 1.071.429 uutta osaketta rekisteröity kaupparekisteriin 08 dec 2023 14:20

Herantis Pharma

Herantis Pharma Oyj: 2.147.710 uutta osaketta rekisteröity kaupparekisteriin 08 dec 2023 07:00

Herantis Pharma

Herantis Pharma on inderesTV December 11th 05 dec 2023 19:45

Herantis Pharma

Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.51 million 01 dec 2023 08:00

Herantis Pharma

Herantis Pharma ilmoittaa HER-096:n prekliinisten tutkimustulosten julkaisusta Cell Chemical Biology -julkaisusarjassa 17 nov 2023 11:15

Herantis Pharma

Herantis Pharma Plc's resolutions of the Extraordinary General Meeting 15 nov 2023 19:25

Herantis Pharma

Herantis Pharma Oyj:n osakkeenomistajien nimitystoimikunnan kokoonpano 01 nov 2023 09:00

Herantis Pharma

Meet Herantis Pharma at BIO-Europe 2023 in Munich, Germany 27 okt 2023 09:45

Herantis Pharma

Kutsu Herantis Pharma Oyj:n ylimääräiseen yhtiökokoukseen 25 okt 2023 09:30

Herantis Pharma

Inside information: Herantis Pharma announces positive topline data from the Phase 1a clinical trial of HER-096, a disease modifying therapeutic developed for Parkinson’s disease 28 sep 2023 08:00

Herantis Pharma

Herantis Pharma osallistuu lokakuussa 2023 neljään tapahtumaan 24 sep 2023 16:00

Herantis Pharma

Sisäpiiritieto: Herantis Pharman CDNF-kehitykseen myönnettyjen lainojen pääomasta jätetään perimättä noin 4,5 miljoonaa euroa Business Finlandin päätöksen mukaisesti 04 sep 2023 16:10

Herantis Pharma

Herantis Pharma osallistuu syyskuussa 2023 Biotech-tapahtumiin: Sachs 23rd Annual Biotech Forum ja ØU Life Science Investor Conference 24 aug 2023 07:00

Herantis Pharma

Herantis Pharma julkaisee vuoden 2023 puolivuosikatsauksen 22 aug 2023 09:30

Herantis Pharma

Herantis Pharma Plc: First healthy volunteers dosed in the part 2 of the HER-096 Phase 1a clinical study 14 aug 2023 12:00

Herantis Pharma

Kutsu Herantis Pharman webinaariin: Yhtiön puolivuosikatsaus 24.8.2023 07 aug 2023 09:00

Herantis Pharma

Herantis Pharma osallistuu kahteen tieteelliseen konferenssiin elokuussa 2023 19 jul 2023 07:00

Herantis Pharma

Herantis Pharma Plc’s shares subscribed with option rights 04 jul 2023 11:05

Herantis Pharma

Herantis Pharma Plc announcing start of recruitment of healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096 20 jun 2023 09:30

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite 20 jun 2023 09:30

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Timo Veromaa 20 jun 2023 09:30

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen 20 jun 2023 09:30

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti 09 jun 2023 13:17

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle 09 jun 2023 13:15

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen 09 jun 2023 13:15

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto 02 jun 2023 14:00

Herantis Pharma

Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel 02 maj 2023 10:45

Herantis Pharma

Herantis Pharma to participate in Bio€quity Europe 2023 in Dublin May 2023 20 apr 2023 12:35

Herantis Pharma

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders 19 apr 2023 10:00

Herantis Pharma

Herantis Pharma announces first healthy volunteer dosed in the Phase 1a clinical study for the Parkinson’s disease drug candidate, HER-096 06 apr 2023 08:00

Herantis Pharma

Herantis Pharma to participate in Nordic Health Summit Japan 2023 28 mar 2023 12:46

Herantis Pharma

Notice to Convene Herantis Pharma Plc's Annual General Meeting of Shareholders 28 mar 2023 07:00

Herantis Pharma

Herantis Pharma published the Annual report for 2022 09 mar 2023 08:00

Herantis Pharma

Herantis Pharma to participate in Bio-Europe Spring and AD/PD 2023 02 mar 2023 07:00

Herantis Pharma

Herantis publishes 2H & FY 2022 Report 21 feb 2023 12:00

Herantis Pharma

Herantis Pharma: Invitation to 2H & FY 2022 report webinar on March 2, 2023 20 feb 2023 12:00

Herantis Pharma

Herantis Pharma announces approval of Clinical Trial Application (CTA) for a Phase 1 study for HER-096 20 jan 2023 09:00

Herantis Pharma

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2023 19 jan 2023 12:00

Herantis Pharma

Herantis Pharma: Key takeaways from todays R&D update webinar 12 jan 2023 08:00

Herantis Pharma

Herantis Pharma to host a R&D update webinar on January 19, 2023 04 jan 2023 08:00

Herantis Pharma

Herantis Pharma to participate in Biotech Showcase and Sachs virtual conferences 22 dec 2022 10:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle 22 dec 2022 10:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto 22 dec 2022 10:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen 20 dec 2022 12:00

Herantis Pharma

Herantis Pharma to host a R&D update webinar January 19, 2023 19 dec 2022 16:30

Herantis Pharma

Herantis Pharma selected for European Innovation Council (EIC) grant of €2.5 million 19 dec 2022 13:15

Herantis Pharma

Herantis Pharma announces submission of a Clinical Trial Application (CTA) for a Phase 1 study for HER-096 15 dec 2022 08:00

Herantis Pharma

Herantis Pharma’s financial calendar and annual general meeting for 2023 07 dec 2022 08:00

Herantis Pharma

Herantis Pharma to participate in Inderes Life Science evening 05 dec 2022 08:00

Herantis Pharma

Herantis Pharma: Approved delisting application regarding the secondary listing on the Nasdaq First North Growth Market Sweden 01 dec 2022 10:30

Herantis Pharma

Herantis Pharma applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden 07 nov 2022 08:00

Herantis Pharma

Herantis Pharma to participate in upcoming November investor conferences 26 okt 2022 16:30

Herantis Pharma

Composition of Herantis Pharma Plc’s Shareholders’ Nomination Committee 05 okt 2022 14:30

Herantis Pharma

Herantis Pharma will attend Bio-Europe 2022 and Redeye Neurology Day 21 sep 2022 16:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto 15 sep 2022 14:30

Herantis Pharma

Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel 07 sep 2022 08:00

Herantis Pharma

Herantis Pharma to Participate in the Nordic Life Science Days, Sweden 25 aug 2022 07:00

Herantis Pharma

Herantis publishes 1H Report for 2022 04 aug 2022 08:00

Herantis Pharma

Herantis Pharma: Invitation to 1H 2022 Report on August 25, 2022 08 jul 2022 12:00

Herantis Pharma

Antti Vuolanto appointed as CEO of Herantis as of 22 July 2022 02 jun 2022 15:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto 02 jun 2022 15:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite 02 jun 2022 15:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle 02 jun 2022 10:10

Herantis Pharma

New shares in Herantis Pharma Plc registered with the trade register 01 jun 2022 19:00

Herantis Pharma

Final results of Herantis Pharma Plc's fully subscribed rights issue 30 maj 2022 18:45

Herantis Pharma

Preliminary results of Herantis Pharma Plc's fully subscribed rights issue 27 maj 2022 12:00

Herantis Pharma

Herantis Pharma to Participate in Redeye Growth Day in June 19 maj 2022 09:04

Herantis Pharma

BioStock: Herantis tar sista steget mot klinik med emission 17 maj 2022 08:38

Herantis Pharma

BioStock Studio: Herantis Pharma om emissionen 13 maj 2022 08:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Timo Veromaa 13 maj 2022 08:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle 13 maj 2022 08:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Frans Wuite 13 maj 2022 08:00

Herantis Pharma

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto 12 maj 2022 10:00

Herantis Pharma

Herantis Pharma: Invitation to a virtual company presentation on May 19, 2022 12 maj 2022 08:33

Herantis Pharma

BioStock: Herantis tf vd om emission och vägen mot klinik 10 maj 2022 08:41

Herantis Pharma

BioStock Investor Pitch: Herantis Pharma 03 maj 2022 18:50

Herantis Pharma

Herantis Pharma Plc's publishes a prospectus relating to its rights issue 03 maj 2022 10:23

Herantis Pharma

Herantis Pharma Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue 02 maj 2022 10:15

Herantis Pharma

Herantis Pharma to Participate in Investor and Partnering Conferences 28 apr 2022 08:00

Herantis Pharma

Herantis Pharma Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs 21 apr 2022 12:20

Herantis Pharma

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders